Literature DB >> 23538783

Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD.

Mark T Dransfield1, Andrew M Wilhelm2, Brian Flanagan3, Clifford Courville3, Sherry L Tidwell4, S Vamsee Raju4, Amit Gaggar4, Chad Steele4, Li Ping Tang5, Bo Liu5, Steven M Rowe6.   

Abstract

BACKGROUND: Cigarette smoke and smoking-induced inflammation decrease cystic fibrosis transmembrane conductance regulator (CFTR) activity and mucociliary transport in the nasal airway and cultured bronchial epithelial cells. This raises the possibility that lower airway CFTR dysfunction may contribute to the pathophysiology of COPD. We compared lower airway CFTR activity in current and former smokers with COPD, current smokers without COPD, and lifelong nonsmokers to examine the relationships between clinical characteristics and CFTR expression and function.
METHODS: Demographic, spirometry, and symptom questionnaire data were collected. CFTR activity was determined by nasal potential difference (NPD) and lower airway potential difference (LAPD) assays. The primary measure of CFTR function was the total change in chloride transport (Δchloride-free isoproterenol). CFTR protein expression in endobronchial biopsy specimens was measured by Western blot.
RESULTS: Compared with healthy nonsmokers (n = 11), current smokers (n = 17) showed a significant reduction in LAPD CFTR activity (Δchloride-free isoproterenol, -8.70 mV vs -15.9 mV; P = .003). Similar reductions were observed in smokers with and without COPD. Former smokers with COPD (n = 7) showed a nonsignificant reduction in chloride conductance (-12.7 mV). A similar pattern was observed for CFTR protein expression. Univariate analysis demonstrated correlations between LAPD CFTR activity and current smoking, the presence of chronic bronchitis, and dyspnea scores.
CONCLUSIONS: Smokers with and without COPD have reduced lower airway CFTR activity compared with healthy nonsmokers, and this finding correlates with disease phenotype. Acquired CFTR dysfunction may contribute to COPD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23538783      PMCID: PMC3734887          DOI: 10.1378/chest.13-0274

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  36 in total

1.  What is cystic fibrosis?

Authors:  Michael R Knowles; Peter R Durie
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

2.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

3.  The many "small COPDs": COPD should be an orphan disease.

Authors:  Stephen I Rennard; Jørgen Vestbo
Journal:  Chest       Date:  2008-09       Impact factor: 9.410

4.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

5.  Deaths: final data for 2007.

Authors:  Jiaquan Xu; Kenneth D Kochanek; Sherry L Murphy; Betzaida Tejada-Vera
Journal:  Natl Vital Stat Rep       Date:  2010-05

6.  Nasal potential difference measurements to assess CFTR ion channel activity.

Authors:  Steven M Rowe; John Paul Clancy; Michael Wilschanski
Journal:  Methods Mol Biol       Date:  2011

7.  Inflammatory cytokines in cystic fibrosis lungs.

Authors:  T L Bonfield; J R Panuska; M W Konstan; K A Hilliard; J B Hilliard; H Ghnaim; M Berger
Journal:  Am J Respir Crit Care Med       Date:  1995-12       Impact factor: 21.405

8.  Role of oxygen availability in CFTR expression and function.

Authors:  Jennifer S Guimbellot; James A Fortenberry; Gene P Siegal; Bryan Moore; Hui Wen; Charles Venglarik; Yiu-Fai Chen; Suzanne Oparil; Eric J Sorscher; Jeong S Hong
Journal:  Am J Respir Cell Mol Biol       Date:  2008-05-12       Impact factor: 6.914

9.  Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology.

Authors:  James C Hogg; Fanny S F Chu; Wan C Tan; Don D Sin; Sanjay A Patel; Peter D Pare; Fernando J Martinez; Robert M Rogers; Barry J Make; Gerard J Criner; Reuben M Cherniack; Amir Sharafkhaneh; James D Luketich; Harvey O Coxson; W Mark Elliott; Frank C Sciurba
Journal:  Am J Respir Crit Care Med       Date:  2007-06-07       Impact factor: 21.405

10.  The mechanism of cystic fibrosis transmembrane conductance regulator transcriptional repression during the unfolded protein response.

Authors:  Rafal Bartoszewski; András Rab; George Twitty; Lauren Stevenson; James Fortenberry; Arkadiusz Piotrowski; Jan P Dumanski; Zsuzsa Bebok
Journal:  J Biol Chem       Date:  2008-03-04       Impact factor: 5.157

View more
  96 in total

1.  Recovery of Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction after Smoking Cessation.

Authors:  Clifford A Courville; S Vamsee Raju; Bo Liu; Frank J Accurso; Mark T Dransfield; Steven M Rowe
Journal:  Am J Respir Crit Care Med       Date:  2015-12-15       Impact factor: 21.405

2.  Neutrophil elastase correlates with increased sphingolipid content in cystic fibrosis sputum.

Authors:  Sophia Karandashova; Apparao Kummarapurugu; Shuo Zheng; Le Kang; Shumei Sun; Bruce K Rubin; Judith A Voynow
Journal:  Pediatr Pulmonol       Date:  2018-04-06

3.  Vaporized E-Cigarette Liquids Induce Ion Transport Dysfunction in Airway Epithelia.

Authors:  Vivian Y Lin; Matthew D Fain; Patricia L Jackson; Taylor F Berryhill; Landon S Wilson; Marina Mazur; Stephen J Barnes; J Edwin Blalock; S Vamsee Raju; Steven M Rowe
Journal:  Am J Respir Cell Mol Biol       Date:  2019-08       Impact factor: 6.914

4.  Anchored PDE4 regulates chloride conductance in wild-type and ΔF508-CFTR human airway epithelia.

Authors:  Elise Blanchard; Lorna Zlock; Anna Lao; Delphine Mika; Wan Namkung; Moses Xie; Colleen Scheitrum; Dieter C Gruenert; Alan S Verkman; Walter E Finkbeiner; Marco Conti; Wito Richter
Journal:  FASEB J       Date:  2013-11-07       Impact factor: 5.191

Review 5.  CFTR pharmacology.

Authors:  Olga Zegarra-Moran; Luis J V Galietta
Journal:  Cell Mol Life Sci       Date:  2016-10-04       Impact factor: 9.261

Review 6.  Ion Channel Modulators in Cystic Fibrosis.

Authors:  Martina Gentzsch; Marcus A Mall
Journal:  Chest       Date:  2018-05-08       Impact factor: 9.410

7.  Serum- and glucocorticoid-induced protein kinase 1 (SGK1) increases the cystic fibrosis transmembrane conductance regulator (CFTR) in airway epithelial cells by phosphorylating Shank2E protein.

Authors:  Katja Koeppen; Bonita A Coutermarsh; Dean R Madden; Bruce A Stanton
Journal:  J Biol Chem       Date:  2014-05-08       Impact factor: 5.157

8.  Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD).

Authors:  George M Solomon; Inez Bronsveld; Kathryn Hayes; Michael Wilschanski; Paola Melotti; Steven M Rowe; Isabelle Sermet-Gaudelus
Journal:  J Vis Exp       Date:  2018-09-13       Impact factor: 1.355

9.  Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function.

Authors:  S Vamsee Raju; Patricia L Jackson; Clifford A Courville; Carmel M McNicholas; Peter A Sloane; Gina Sabbatini; Sherry Tidwell; Li Ping Tang; Bo Liu; James A Fortenberry; Caleb W Jones; Jeremy A Boydston; J P Clancy; Larry E Bowen; Frank J Accurso; J Edwin Blalock; Mark T Dransfield; Steven M Rowe
Journal:  Am J Respir Crit Care Med       Date:  2013-12-01       Impact factor: 21.405

10.  A ferret model of COPD-related chronic bronchitis.

Authors:  S Vamsee Raju; Hyunki Kim; Stephen A Byzek; Li Ping Tang; John E Trombley; Patricia Jackson; Lawrence Rasmussen; J Michael Wells; Emily Falk Libby; Erik Dohm; Lindy Winter; Sharon L Samuel; Kurt R Zinn; J Edwin Blalock; Trenton R Schoeb; Mark T Dransfield; Steven M Rowe
Journal:  JCI Insight       Date:  2016-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.